Warning: This site requires Javascript to be enabled in order to function as expected.

#smooth-wrapper { height: auto !important; }

Skip to content

Tangram Therapeutics | Committed to uniting computation, RNAi, and unconventional thinking to make better medicines faster.

Press release

Interim Results for six months ended 31 July 2018

4 October 2018

Data too large for file format

Tags

Share
Sign up for press releases

Discover

Whats New?

Press release

Tangram Therapeutics Announces Progression to Patient Cohorts in Phase 1/2 RESTORE-MASH Trial of TGM-312 and Appointment of Dr Sonya Montgomery as Chief Development Officer

Sep 3, 2026

Press release

Tangram Therapeutics Announces Appointment of Laura Roca-Alonso, Ph.D. as Interim Chief Executive Officer

Mar 30, 2026

Press release

Tangram Therapeutics Announces First Participant Dosed in Phase 1/2 RESTORE-MASH Trial of TGM-312, a Novel Investigational RNAi Medicine

Mar 5, 2026

Press release

Tangram Therapeutics Submits Clinical Trial Application for Phase 1/2 Study of TGM-312, a Novel Investigational RNAi MASH Candidate

Nov 26, 2025

Press release

Tangram Therapeutics to Participate in Upcoming Investor and Scientific Conferences

Oct 3, 2025

Press release

e-therapeutics Relaunches as Tangram Therapeutics and Unveils LLibra OS

Oct 1, 2025

/